Phase 2 study reports significantly accelerated debridement and wound repair in venous leg ulcers
Phase 2 study reports significantly accelerated debridement and wound repair in venous leg ulcers
New phase 3 results highlight potential alternative for adults switching from complex regimens
More than 200 participants enrolled as company targets topline data by end of 2026
Oral therapy authorised for ER‑positive, HER2‑negative metastatic disease with ESR1 mutations
Erythromelalgia treatment gains regulatory support following EMA decision
PASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens
QUASAR long‑term extension results highlight durable clinical and endoscopic outcomes
MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups
Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD
Basque company becomes first authorised under new European SoHO rules
European Commission backs first ultra‑long‑acting biologic for respiratory disease
Move expands iPSC‑derived retinal model portfolio and strengthens position in research
Collaboration aims to speed access to challenging targets through an AI‑guided workflow
Bocunebart shows significant reduction in monthly migraine days in patients with previous treatment failures
New group aims to address structural barriers holding back Europe’s biotech scale‑up